Lupin Ltd

  • BSE Code : 500257
  • NSE Symbol : LUPIN
  • ISIN : INE326A01037
  • Industry :PHARMACEUTICALS - INDIAN - BULK DRUGS & FORMLN

up-arrow 2,290.70 -24.20(-1.05%)

Open Price ()

2,301.10

Prev. Close ()

2,314.90

Volume (No’s)

305,271

Market Cap ()

105,800.93

Low Price ()

2,251.00

High Price ()

2,312.00

 

Board Meetings

Start Date End Date Purpose
28-Jan-2026 12-Feb-2026 Lupin Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31 2025. Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2025. Outcome of the Board Meeting for Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter and Nine Months ended December 31, 2025. (As Per BSE Announcement Dated on 12.02.2026)
06-Jan-2026 06-Jan-2026 Appointment of Mr. Anand Kripalu as an Additional Director (Non-Executive, Independent) effective February 01, 2026 and as an Independent Director for a term of five consecutive years with effect from February 01, 2026
22-Oct-2025 06-Nov-2025 Lupin Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2025 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30 2025. Outcome of the Board Meeting for Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter and Half Year ended September 30, 2025. (As Per BSE Announcement Dated on 06.11.2025)
21-Jul-2025 05-Aug-2025 Lupin Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2025 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter Ended June 30 2025. Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2025. (As Per BSE Announcement Dated on: 05.08.2025)
29-Apr-2025 14-May-2025 Lupin Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2025 inter alia to consider and approve Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31 2025 and recommend dividend if any. Outcome of Board Meeting - Audited Financial Results for the quarter and year ended March 31, 2025 and recommendation of Dividend Recommended a Dividend of ? 12/- (Rupees Twelve only) per Equity Share (i.e. 600%) of the face value of ? 2/- (Rupees Two only) each fully paid up, for the financial year ended March 31, 2025, subject to approval of the Members at the ensuing Annual General Meeting (AGM'). The Dividend shall be paid within 30 days from the date of approval by the Members at the ensuing AGM. (As Per BSE Announcement Dated on 14.05.2025)

Copyright © 2026 Arihant Capital Markets Ltd. All rights Reserved.

Designed, Developed and Content powered by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)

x
  • QR-CodeNew